HROW
Price
$31.75
Change
+$1.18 (+3.86%)
Updated
Jul 3 closing price
Capitalization
467.85M
38 days until earnings call
RDY
Price
$15.08
Change
+$0.20 (+1.34%)
Updated
Jul 3 closing price
Capitalization
12.48B
18 days until earnings call
Interact to see
Advertisement

HROW vs RDY

Header iconHROW vs RDY Comparison
Open Charts HROW vs RDYBanner chart's image
Harrow
Price$31.75
Change+$1.18 (+3.86%)
Volume$257.7K
Capitalization467.85M
Dr. Reddy's Laboratories
Price$15.08
Change+$0.20 (+1.34%)
Volume$583.44K
Capitalization12.48B
HROW vs RDY Comparison Chart in %
Loading...
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HROW vs. RDY commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a Hold and RDY is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (HROW: $31.75 vs. RDY: $15.08)
Brand notoriety: HROW and RDY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: HROW: 60% vs. RDY: 36%
Market capitalization -- HROW: $467.85M vs. RDY: $12.48B
HROW [@Pharmaceuticals: Other] is valued at $467.85M. RDY’s [@Pharmaceuticals: Other] market capitalization is $12.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HROW’s FA Score shows that 1 FA rating(s) are green whileRDY’s FA Score has 1 green FA rating(s).

  • HROW’s FA Score: 1 green, 4 red.
  • RDY’s FA Score: 1 green, 4 red.
According to our system of comparison, RDY is a better buy in the long-term than HROW.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HROW’s TA Score shows that 3 TA indicator(s) are bullish while RDY’s TA Score has 4 bullish TA indicator(s).

  • HROW’s TA Score: 3 bullish, 5 bearish.
  • RDY’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RDY is a better buy in the short-term than HROW.

Price Growth

HROW (@Pharmaceuticals: Other) experienced а +1.28% price change this week, while RDY (@Pharmaceuticals: Other) price change was -1.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.02%. For the same industry, the average monthly price growth was +2.94%, and the average quarterly price growth was +92.60%.

Reported Earning Dates

HROW is expected to report earnings on Aug 12, 2025.

RDY is expected to report earnings on Jul 23, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.02% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RDY($12.5B) has a higher market cap than HROW($468M). HROW has higher P/E ratio than RDY: HROW (39.53) vs RDY (19.68). RDY YTD gains are higher at: -4.497 vs. HROW (-5.365). RDY has higher annual earnings (EBITDA): 84.9B vs. HROW (9.95M). RDY has more cash in the bank: 72.4B vs. HROW (82.8M). HROW has less debt than RDY: HROW (191M) vs RDY (19.9B). RDY has higher revenues than HROW: RDY (271B) vs HROW (130M).
HROWRDYHROW / RDY
Capitalization468M12.5B4%
EBITDA9.95M84.9B0%
Gain YTD-5.365-4.497119%
P/E Ratio39.5319.68201%
Revenue130M271B0%
Total Cash82.8M72.4B0%
Total Debt191M19.9B1%
FUNDAMENTALS RATINGS
HROW vs RDY: Fundamental Ratings
HROW
RDY
OUTLOOK RATING
1..100
6777
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
81
Overvalued
PROFIT vs RISK RATING
1..100
5132
SMR RATING
1..100
9748
PRICE GROWTH RATING
1..100
4451
P/E GROWTH RATING
1..100
1157
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

HROW's Valuation (77) in the Pharmaceuticals Other industry is in the same range as RDY (81) in the Pharmaceuticals Generic industry. This means that HROW’s stock grew similarly to RDY’s over the last 12 months.

RDY's Profit vs Risk Rating (32) in the Pharmaceuticals Generic industry is in the same range as HROW (51) in the Pharmaceuticals Other industry. This means that RDY’s stock grew similarly to HROW’s over the last 12 months.

RDY's SMR Rating (48) in the Pharmaceuticals Generic industry is somewhat better than the same rating for HROW (97) in the Pharmaceuticals Other industry. This means that RDY’s stock grew somewhat faster than HROW’s over the last 12 months.

HROW's Price Growth Rating (44) in the Pharmaceuticals Other industry is in the same range as RDY (51) in the Pharmaceuticals Generic industry. This means that HROW’s stock grew similarly to RDY’s over the last 12 months.

HROW's P/E Growth Rating (11) in the Pharmaceuticals Other industry is somewhat better than the same rating for RDY (57) in the Pharmaceuticals Generic industry. This means that HROW’s stock grew somewhat faster than RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HROWRDY
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
65%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 3 days ago
59%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
43%
MACD
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
53%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
51%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
46%
Advances
ODDS (%)
Bullish Trend 25 days ago
83%
Bullish Trend 24 days ago
51%
Declines
ODDS (%)
Bearish Trend 6 days ago
81%
Bearish Trend 4 days ago
51%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
39%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
HROW
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RDY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KAUAX6.050.07
+1.17%
Federated Hermes Kaufmann A
FWOZX17.510.13
+0.75%
Fidelity Advisor Women's Leadership Z
GTLOX20.710.15
+0.73%
Glenmede Disciplined US Eq Ptf
SVPSX81.600.38
+0.47%
ProFunds Small Cap Value Svc
JMVNX15.240.06
+0.40%
JHFunds2 Mid Value NAV

HROW and

Correlation & Price change

A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AMRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HROW
1D Price
Change %
HROW100%
+3.86%
AMRX - HROW
47%
Loosely correlated
+0.60%
EBS - HROW
39%
Loosely correlated
-1.69%
OGI - HROW
35%
Loosely correlated
+3.62%
TLRY - HROW
33%
Poorly correlated
+11.03%
AMPH - HROW
32%
Poorly correlated
-1.61%
More

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and COLL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and COLL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
+1.34%
COLL - RDY
31%
Poorly correlated
-0.52%
KMDA - RDY
28%
Poorly correlated
+1.81%
AMPH - RDY
26%
Poorly correlated
-1.61%
OGI - RDY
26%
Poorly correlated
+3.62%
HROW - RDY
25%
Poorly correlated
+3.86%
More